FGF21在心力衰竭中的作用:分子见解和治疗影响
Siddharth Pravin Agrawal1, Lana Tannous1, Ritu C Tated2
1From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.
Cardiology in review
|November 6, 2025
概括
纤维细胞生长因子21 (FGF21) 显示出作为心力衰竭生物标志物和治疗标的前景. FGF21类似物可能会对心血管有好处,但需要进一步的研究来澄清其作用并确保安全.
科学领域:
- 心血管研究研究心血管研究
- 代谢内分泌学代谢内分泌学
- 分子医学是分子医学.
背景情况:
- 纤维细胞生长因子21 (FGF21) 是一种代谢激素,在临床前心力衰竭 (HF) 模型中显示出心脏保护作用.
- FGF21调节关键的代谢途径和与心脏健康相关的细胞应激反应.
- 患有高血压的人类FGF21水平升高表明补偿作用和潜在的"FGF21耐药性".
研究的目的:
- 审查心力衰竭中FGF21的分子机制,临床前证据和临床数据.
- 评估FGF21作为预后生物标志物和高风暴治疗标的潜力.
- 讨论FGF21类型的临床实用性,并确定未来的研究方向.
主要方法:
- 分子,临床前 (实验模型) 和临床证据的整合.
- 分析FGF21在各种HF病因中的作用 (压力过重,缺血-再输,心脏毒性,糖尿病心肌病).
- 评估循环FGF21水平及其与HF严重程度和结果的相关性.
主要成果:
- 在实验中,FGF21通过增强新陈代谢,自和抗氧化剂防御,同时减少炎症和纤维化,显示出保护作用.
- 循环FGF21水平在人体HF中升高,与不良重塑和不良预后相关.
- 用于代谢性疾病的FGF21类似物显示出潜在的心血管益处.
结论:
- FGF21是一种重要的代谢激素,具有双重作用,作为潜在的生物标志物和心力衰竭的治疗剂.
- 需要进一步的研究,以阐明FGF21在人类HF进展中的确切作用以及治疗类型的有效性/安全性.
- 专注于FGF21的转化策略可能为HF管理提供新的方法.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:27Heart Failure I: Introduction
671
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
671
01:22Heart Failure VI: Adjunct Therapies
243
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
243